Finbar Larkin, Ph.D., was appointed Senior Vice President, Technical Operations in October 2019. He has been a member of the Jazz family since 2013 and has made significant contributions to Jazz’s evolution and transformation to an innovative Biopharma company. He built the pharmaceutical development and manufacturing science organization responsible for Chemistry Manufacturing and Controls (CMC) activities related to development, approval and launch of Sunosi, Xywav, Defitelio and Vyxeos. Dr. Larkin has responsibility for global pharmaceutical CMC development, manufacturing, supply chain, and new product and technology integration.
Dr. Larkin was appointed our Senior Vice President, Technical Operations in October 2019. Dr. Larkin previously served as our Senior Vice President, Pharmaceutical Development & Manufacturing Science from September 2018 until October 2019, our Vice President, Technical Development from February 2014 until August 2018, and our Executive Director, Technical Operations from April 2013 until February 2014. Prior to that, from September 2009 until March 2013, Dr. Larkin served in management roles at Ipsen Pharma SAS, culminating in his role as Vice President, Engineering & Senior Specialist. From February 1997 until August 2009, he served as Vice President and Managing Director at Ipsen Manufacturing Ireland. From 1990 until 1997, he served in various project and operational management roles at Novartis. Prior to 1990, Dr. Larkin served in various roles in manufacturing science and technology, human resources and quality & analytical science at Lilly SA. Dr. Larkin received a B.Sc. and Ph.D. in Chemistry from University College Dublin.
What is Finbar Larkin's net worth?
The estimated net worth of Finbar Larkin is at least $2.95 million as of March 6th, 2023. Dr. Larkin owns 23,854 shares of Jazz Pharmaceuticals stock worth more than $2,951,455 as of December 24th. This net worth approximation does not reflect any other investments that Dr. Larkin may own. Learn More about Finbar Larkin's net worth.
How do I contact Finbar Larkin?
Has Finbar Larkin been buying or selling shares of Jazz Pharmaceuticals?
Finbar Larkin has not been actively trading shares of Jazz Pharmaceuticals over the course of the past ninety days. Most recently, Finbar Larkin sold 1,706 shares of the business's stock in a transaction on Monday, March 6th. The shares were sold at an average price of $143.92, for a transaction totalling $245,527.52. Following the completion of the sale, the senior vice president now directly owns 23,854 shares of the company's stock, valued at $3,433,067.68. Learn More on Finbar Larkin's trading history.
Who are Jazz Pharmaceuticals' active insiders?
Jazz Pharmaceuticals' insider roster includes Paul Berns (Director), Patricia Carr (SVP), Jennifer Cook (Director), Bruce Cozadd (Co-Founder, Chairman & CEO), Patrick Enright (Director), Renée Galá (CFO), Peter Gray (Director), Mary Henderson (SVP, Technical Operations), Robert Iannone (EVP), Philip Johnson (CFO), Finbar Larkin (SVP), Seamus Mulligan (Director), Kenneth O'Keefe (Director), Anne Oriordan (Director), Neena Patil (Insider), Samantha Pearce (SVP), Kim Sablich (EVP), Elmar Schnee (Director), Mark Smith (Director), Christopher Tovey (COO), and Rick Winningham (Director). Learn More on Jazz Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Jazz Pharmaceuticals?
During the last year, Jazz Pharmaceuticals insiders bought shares 1 times. They purchased a total of 12,000 shares worth more than $1,435,800.00. During the last year, insiders at the specialty pharmaceutical company sold shares 8 times. They sold a total of 15,262 shares worth more than $1,766,604.30. The most recent insider tranaction occured on December, 2nd when CEO Bruce C Cozadd sold 2,000 shares worth more than $242,340.00. Insiders at Jazz Pharmaceuticals own 4.2% of the company.
Learn More about insider trades at Jazz Pharmaceuticals. Information on this page was last updated on 12/2/2024.
